Search

Your search keyword '"Delimpasi, Sosana"' showing total 533 results

Search Constraints

Start Over You searched for: Author "Delimpasi, Sosana" Remove constraint Author: "Delimpasi, Sosana"
533 results on '"Delimpasi, Sosana"'

Search Results

1. Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group

3. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

5. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

6. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

7. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

8. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

9. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

10. Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study Group.

11. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

12. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).

13. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

14. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

15. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

16. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study

17. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA

18. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

19. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

20. MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis

21. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

22. P-455 Survey of multiple myeloma (MM) patients and healthcare professionals (HCPs) on the relevance of existing health quality-of-life (QoL) questionnaires (QoLQ) to real-world QoL issues of MM patients

23. P-245 Belantamab mafodotin in patients with severely impaired renal function: a phase I, 2-part study to evaluate pharmacokinetics, safety and efficacy in patients with relapsed/refractory multiple myeloma

24. P-454 Patients views on the relevance of quality of life (QoL) questionnaires commonly applied to evaluate the QoL of patients with AL amyloidosis

25. MM-509 A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)

26. P-319 Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the Phase 2 study DARIA

27. P-213 COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)

28. P-117 A prognostic score based on age, eGFR (CKD-EPI), performance status and ultra-high-risk disease outperforms R2-ISS for elderly myeloma patients: an analysis of the Greek myeloma study group registry

30. POSTER: MM-509 A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM3)

31. P-457 Waldenstrom's Macroglobulinaemia (WM) patients' online survey -currently available QoLQs not representative of real-world health quality-of-life (QoL) issues of WM patients

32. S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)

33. P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY

34. P920: EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA STUDY GROUP EXPERIENCE.

35. P897: EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI-MYELOMA TREATMENTS ON POST- PROGRESSION OUTCOMES IN THE REAL-WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE.

36. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group

37. Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study.

38. Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

39. Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study Group

40. Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

41. Survey of the Relevance of Quality of Life (QoL) Questionnaires (QoLQs) Currently Used to Evaluate Multiple Myeloma (MM) Patients' Qol in Real-World MM Patients and Healthcare Professionals (HCPs)

42. Poster: MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis

43. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies

44. Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.

45. OAB-046: Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis

46. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

47. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

48. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

49. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial

50. Supplementary files of the article Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial [Dataset]

Catalog

Books, media, physical & digital resources